A Controlled Trial Comparing Foscarnet with Vidarabine for Acyclovir-Resistant Mucocutaneous Herpes Simplex in the Acquired Immunodeficiency Syndrome

INFECTIONS with acyclovir-resistant herpes simplex virus in patients with human immunodeficiency virus (HIV) infection may progress inexorably if untreated, becoming a source of severe pain, disfigurement, and bacterial superinfection. 1 2 3 4 5 6 7 8 9 In all the index isolates tested from patients...

Full description

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 325; no. 8; pp. 551 - 555
Main Authors Safrin, Sharon, Crumpacker, Clyde, Chatis, Pam, Davis, Roger, Hafner, Richard, Rush, Joanne, Kessler, Harold A, Landry, Bernard, Mills, John
Format Journal Article
LanguageEnglish
Published Boston, MA Massachusetts Medical Society 22.08.1991
Subjects
Acquired immune deficiency syndrome
Acyclovir
AIDS
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral agents
Biological and medical sciences
Body weight
Deoxyribonucleic acid
Disease resistance
DNA
Drug therapy
Foscarnet
Herpes simplex
herpes simplex virus
Herpes viruses
HIV
Hospitals
Human immunodeficiency virus
Immunodeficiency
Infections
Infectious diseases
Intravenous administration
Kinases
Laboratories
Medical sciences
Medicine
Pain
Pharmacology. Drug treatments
Toxicity
Human
Immunopathology
Drug combination
Herpesviridae
Alphaherpesvirinae
AIDS
Hemopathy
Infection
Virus
Chemotherapy
Treatment
Viral disease
Antiviral
Mucocutaneous
Herpesvirus hominis
Online AccessGet full text

Cover

More Information
Summary:INFECTIONS with acyclovir-resistant herpes simplex virus in patients with human immunodeficiency virus (HIV) infection may progress inexorably if untreated, becoming a source of severe pain, disfigurement, and bacterial superinfection. 1 2 3 4 5 6 7 8 9 In all the index isolates tested from patients with HIV infection who have acyclovir-resistant herpes simplex infection, the activity of the viral thymidine kinase enzyme has been markedly decreased or absent. 3 , 4 , 7 8 9 Also, all such isolates have been susceptible in vitro to both vidarabine (adenine arabinoside) and foscarnet (phosphonoformic acid), neither of which requires activation by the viral thymidine kinase. Vidarabine is effective in the treatment of neonatal herpes simplex infection and . . .
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJM199108223250805